Analyst Ratings For AnaptysBio (NASDAQ:ANAB)
Today, Robert W. Baird reiterated its Buy rating on AnaptysBio (NASDAQ:ANAB) with a price target of $144.00.
Some recent analyst ratings include
- 1/19/2018-Robert W. Baird Reiterated Rating of Buy.
- 11/15/2017-SunTrust Banks initiated coverage with a Buy rating.
- 11/9/2017-Jefferies Group initiated coverage with a Buy rating.
- 11/7/2017-Wedbush Reiterated Rating of Outperform .
- 10/13/2017-Stifel Nicolaus Reiterated Rating of Buy.
- On 8/21/2017 Holdings A/S Novo, Major Shareholder, sold 356,300 with an average share price of $21.10 per share and the total transaction amounting to $7,517,930.00.
- On 8/15/2017 Holdings A/S Novo, Major Shareholder, sold 178,600 with an average share price of $21.16 per share and the total transaction amounting to $3,779,176.00.
- On 8/7/2017 Holdings A/S Novo, Major Shareholder, sold 491,294 with an average share price of $21.12 per share and the total transaction amounting to $10,376,129.28.
- On 8/3/2017 Holdings A/S Novo, Major Shareholder, sold 70,706 with an average share price of $23.31 per share and the total transaction amounting to $1,648,156.86.
- On 7/26/2017 Ventures Vii L P Avalon, Major Shareholder, sold 37,040 with an average share price of $24.35 per share and the total transaction amounting to $901,924.00.
- On 1/31/2017 Healthcare Vii L.P. Frazier, Major Shareholder, bought 400,000 with an average share price of $15.00 per share and the total transaction amounting to $6,000,000.00.
- On 1/31/2017 Nicholas Lydon, Director, bought 16,666 with an average share price of $15.00 per share and the total transaction amounting to $249,990.00.
Recent Trading Activity for AnaptysBio (NASDAQ:ANAB)
Shares of AnaptysBio closed the previous trading session at 112.00 up +1.55 1.40% with 110.66000366210938 shares trading hands.